Metsera, Inc. MTSR
At closeNov 13, 2025, 4:00 PM EST
52-week range unavailable
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 7.43B
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 27.87M
- Open
- 70.74
- Previous close
- 70.50
- Day's range
- 70.13 – 70.76
- Earnings date
- Mar 25, 2026
2Y +44.00 (+166.04%)
Key statistics
- Enterprise value
- 6.98B
- PEG ratio
- -16.63
- Price / sales
- 0.00
- Price / book
- 21.96
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -47.04%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 25, 2026
Expected Mar 25, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 25, 2026 | Dec 31, 2025 | -0.54 | — | — | — |
| Nov 12, 2025 | Sep 30, 2025 | -0.56 | -1.11 | -0.55 | -98.21% |
| Jul 28, 2025 | Jun 30, 2025 | -0.65811 | -0.66 | 0.00 | -0.29% |
| May 12, 2025 | Mar 31, 2025 | -0.85 | -1.03 | -0.18 | -21.18% |
| Mar 26, 2025 | Dec 31, 2024 | -0.80 | -3.52 | -2.72 | -340.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 24, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Sep 9, 2025 | Leerink Partners | init | — | Outperform |
| Sep 3, 2025 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 28, 2025 | B of A Securities | main | Buy | Buy |
| Jun 20, 2025 | Wells Fargo | init | — | Overweight |
| Jun 10, 2025 | Guggenheim | main | Buy | Buy |
About Metsera, Inc.
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 93
- Website
- pfizer.com
News
Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside 
IP Group shares jump 9% as Metsera deal drives return to growth 
Metsera Inc. (NASDAQ:MTSR) Given Average Recommendation of “Hold” by Brokerages 
Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market 
Ozempic Maker Novo Nordisk Faces Board Shakeup 
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields 
Pfizer Completes Acquisition of Metsera 
Metsera shareholders vote for $10 billion acquisition by Pfizer 
Why Metsera's Share Price Is Plummeting This Week 
Instacart Up on Earnings Beat; Metsera Down on Takeover Battle | Stock Movers
Your note
Sign in to keep a note on MTSR — it syncs with the Stock Master app.